GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

LXRX · Jun 30, 2024

LEXICON PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001062822-24-000046General Corporate

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

15.46% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-3001.86% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

36.18% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

89.73% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-3423.25% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1091.09% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

303.03% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History10 statesHistory building

Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20240/7 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20250/7 normalizedLevel 3 Sep 30, 20250/8 normalizedLevel 3 Dec 31, 20250/9 normalizedLevel 3 Mar 31, 20266/8 normalizedLevel 3 Jun 30, 20266/8 normalizedLevel 3

Period transition

What moved in the state?

Capex Intensity Increased

Previous: 0.00%
Current: 15.46%
Delta: 15.46%

Cash Generation Increased

Previous: -5043.92%
Current: -3001.86%
Delta: 2042.06%

Inventory Pressure Decreased

Previous: 47.03%
Current: 36.18%
Delta: -10.85%

Margin Decreased

Previous: 97.16%
Current: 89.73%
Delta: -7.43%

Profitability Increased

Previous: -4147.58%
Current: -3423.25%
Delta: 724.32%

R And D Intensity Decreased

Previous: 1314.91%
Current: 1091.09%
Delta: -223.82%

Sbc Intensity Decreased

Previous: 393.60%
Current: 303.03%
Delta: -90.57%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · LXRX Fundamental State →Has State · LEXICON PHARMACEUTICALS, INC. →Transitioned To · LXRX Fundamental State →Transitioned To · LXRX CAPEX_INTENSITY_INCREASED →Transitioned To · LXRX CASH_GENERATION_INCREASED →Transitioned To · LXRX INVENTORY_PRESSURE_DECREASED →Transitioned To · LXRX MARGIN_DECREASED →Transitioned To · LXRX PROFITABILITY_INCREASED →Transitioned To · LXRX R_AND_D_INTENSITY_DECREASED →Transitioned To · LXRX SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.